All Articles

Onfolio Holdings reports 36% revenue growth and positive EBITDA, but a wider net loss and auditor warnings reveal a high-stakes strategy for 2026.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

A landmark report from BC's counsellors' association pioneers a new era of transparency, linking operations to public trust and quality of care.

The energy services firm reports a 90% jump in adjusted EBITDA, crediting disciplined spending and a lucrative foray into the Alaskan snubbing market.

A scathing new report reveals systemic failures in federal Indigenous procurement, validating long-standing calls to end 'gilding' and phantom ventures.

The merger meant to launch a new-economy bank now includes a massive iron mine, raising questions about strategy, valuation, and management expertise.

A new $13.8M federal investment in BC's AI and aerospace sectors aims to bolster national security, meet NATO goals, and spur economic growth.

With a seasoned team and $253 million in fresh capital, Inflection Point's new SPAC signals strong investor confidence in a disciplined market.

A new FDA-cleared chair offers a non-invasive solution for bladder leakage, but how does the technology stack up in a rapidly growing market?

Securityholders overwhelmingly approve a C$0.90 per share cash offer from Mansa Resources, paving the way for the Dugbe Gold Project's private development.

The Our Health Our Wellness campaign aims to close critical health disparity gaps with resources, events, and education for underserved communities.

The luxury brand missed Q4 estimates, citing market challenges, but CEO Gary Friedman laid out a bold, multi-year path for global expansion and growth.

JFrog's new plugin for the Cursor AI editor embeds software supply chain security directly into developer workflows, aiming to tame the risks of autonomous coding.

With Stacy Walton as its first CCO, Longitude Rx signals a major push to disrupt specialty pharmacy and empower health systems against market headwinds.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

The American Skin Association launches SKINsight, a podcast series uniting top doctors and patients to demystify skin disease for millions of listeners.

Banking tech leader nCino posts record FY2026 results, fueling a major stock buyback and signaling deep confidence in its AI-driven global strategy.

Concord's new SVP of Sales, Andrew Coffey, brings deep operational experience, signaling a strategic shift to prioritize execution in a competitive market.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

The carbon-tech firm slashes losses and touts a key SAF partnership, but dwindling cash reserves raise questions about its path to sustainable growth.